A recombinant shingles vaccine appears to be associated with a lower risk of cardiovascular events, according to a report by Deutsches Ärzteblatt. The finding, published on August 28, 2026, adds to growing evidence that the shot may offer benefits beyond its primary purpose of preventing shingles.
The report, which draws on recent research covered by multiple outlets, indicates that people who received the recombinant zoster vaccine showed a reduced likelihood of conditions such as heart attack and stroke. Deutsches Ärzteblatt highlighted this association as a notable development in vaccine research, though the exact mechanism behind the potential protective effect remains unclear.
Other German-language publications, including Pharmazeutische Zeitung, Spektrum der Wissenschaft, Der Standard, and WELT, have also picked up the story, describing the vaccine as possibly shielding both the heart and the brain. One outlet quoted a source calling the shot "one of the most effective measures" for such protection, though no specific study details or patient data were included in the available summary.
